Introduction
============

Nivolumab is a fully human immunoglobulin G4 monoclonal antibody which binds and blocks programmed death-1 (PD-1) receptors on cancer cell membranes, resulting in the release of cancer immune-tolerance. Its development has drastically changed the treatment of various cancers including advanced melanoma and non-small cell lung cancer ([@B1]-[@B3]). Despite its clinical benefits, nivolumab also induces a variety of immune-related adverse events. For example, clinical trials revealed that nivolumab caused interstitial lung disease (ILD) with the incidence ranging from 1.3 to 5.0% ([@B4]). However, the detailed clinical and pathological manifestations of nivolumab-induced ILD remain unclear.

On the other hand, acute fibrinous and organizing pneumonia (AFOP) is a rare type of ILD characterized by intra-alveolar fibrin balls and organizing pneumonia with a patchy distribution ([@B5]). The present report describes a patient with advanced melanoma who developed nivolumab-induced ILD, where a lung biopsy established a pathological diagnosis of AFOP.

Case Report
===========

A 68-year-old man with advanced melanoma in the ethmoidal sinus was referred to our institution for treatment. He had been treated with heavy-ion particle irradiotherapy (57.6 GyE/16 fr) 9 months ago because the disease was locoreginal and unresectable. Although a combination chemotherapy regimen consisting of dacarbazine, nimustine and vincristine had been started immediately after irradiation, multiple bone and pulmonary metastases developed shortly after one cycle of chemotherapy. Then, after being referred to our institution, nivolumab at a dose of 2 mg/kg, every 3 weeks, was administered, which thus resulted in a complete response. The treatment was continued for 30 weeks until admission to our hospital because of a worsening dyspnea and non-productive cough. The onset of dyspnea developed 3 days before admission. On examination, his body temperature was 36.8℃ and oxygen saturation on room air was 89%. His physical examination was unremarkable. Despite normal findings at 15 weeks before the onset of dyspnea ([Fig. 1A and B](#g001){ref-type="fig"}), computed tomography (CT) images on admission revealed patchy infiltrates and ground-glass opacifications with interlobular septal thickening ([Fig. 1C and D](#g001){ref-type="fig"}). Laboratory tests demonstrated white blood cell counts of 12,200 /μL with 76.4% neutrophils and 8.8% lymphocytes, C-reactive protein level of 20.9 mg/dL (normal \<0.3 mg/dL), serum lactate dehydrogenase (LDH) level of 215 IU/L (normal, 119-229 IU/L), and KL-6 level of 183 U/mL (normal \<500 U/mL). Electrolytes, creatinine, liver function tests were normal. Rheumatoid factor, anti-nuclear antibody and proteinase 3 (PR-3)- and myeloperoxidase (MPO) anti-neutrophil cytoplasmic antibodies were negative. Anti-cytomegalovirus antibody and beta-glucan were below the detection limits. Bronchoalveolar lavage fluid (BALF) contained 600 nucleated cells/mm^3^, including lymphocytes (53.6%: CD4/CD8 was not evaluated because the bronchoalveolar lavage (BAL) was performed in an emergency setting), macrophages (5.7%), neutrophils (30.1%), and eosinophils (10.6%). A culture of the BALF was negative. Transbronchial lung biopsy revealed intraalveolar fibrin balls without hyaline membranes which was consistent with the pattern of AFOP ([Fig. 2A](#g002){ref-type="fig"}). In contrast to the presence of lymphocytosis, neutrophilia and eosinophilia in the BALF, no marked infiltration of the inflammatory cells was observed in the alveolar septum, alveolar spaces and adjacent to the vascular structures. The absence of marked neutrophilia in lung tissue ruled out a diagnosis of acute respiratory distress syndrome ([Fig. 2B](#g002){ref-type="fig"}). High dose corticosteroid administration (intravenous methylprednisolone at a dose of 1,000 mg for 3 days, followed by oral prednisolone at a dose of 1 mg/kg) was started, and the treatment was effective for ameliorating dyspnea as well as for improving the imaging findings ([Fig. 1E and F](#g001){ref-type="fig"}). During the treatment with corticosteroid and without nivolumab, colitis with persistent diarrhea developed. Although the colitis was resolved with continuing corticosteroid and 2 shots of infliximab at a dose of 5 mg/kg, he died because of tumor relapse at the skull base in 4 months after the discontinuation of nivolumab. An autopsy was not permitted.

![CT images. Chest CT images after treatment with nivolumab and at 15 weeks before the onset of dyspnea show normal findings (A, B). At the onset of ILD, multiple bilateral patchy infiltrates and ground glass attenuation with interlobular septal thickening developed (C, D). After treatment with corticosteroids, these findings all improved (E, F). ILD: interstitial lung disease](1349-7235-56-2311-g001){#g001}

![Pathological findings. Pathological evaluation of the lung revealed intraalveolar filling with fibrin balls (arrows) without hyaline membrane formation, thereby establishing the pathological diagnosis of acute fibrinous and organizing pneumonia \[Hematoxylin and Eosin staining, original magnification of ×10 in (A) and ×20 in (B)\].](1349-7235-56-2311-g002){#g002}

Discussion
==========

Although it is challenging to diagnose drug-induced ILD because various other conditions should first be excluded, we diagnosed the present case as being nivolumab-induced. A negative culture of BALF, negative serological findings including autoantibodies, cytomegalovirus antibody and beta-glucan, and no usage of new drugs except for nivolumab might also rule out other etiologies for ILD.

The radiologic features of the present patient were characterized by patchy infiltrates and ground-glass opacifications with interlobular septal thickening. Retrospective radiology review of 27 patients with anti-PD-1/PD-L1 induced pneumonitis showed that ground-glass opacifications were the most common subtype (37%), and that interstitial pattern including interlobular septal thickening was observed in 22% of patients ([@B6]). These findings seem concordant to the radiologic characteristics of the present patient. An accumulation of over-activated T lymphocytes into the lymphatic tracts may cause an abnormal widening of the interlobular septa in this case, because interlobular septal thickening is also observed in patients with pulmonary edema, lymphangitic carcinomatosis, and pulmonary lymphoma which are related to an abnormality in lymphatic tract surrounding the pulmonary lobules. As a result, further investigation is needed to elucidate the underlying mechanism.

Among the 9 previously reported cases identified as nivolumab- or another anti-PD-1 antibody pembrolizumab-induced ILD, only 3 cases had a pathological diagnosis of ILD consisting of diffuse alveolar damage in one case and organizing pneumonia in 2 cases ([Table](#t001){ref-type="table"}) ([@B7]-[@B13]). Therefore, this report seems very unique in linking AFOP to a new type of nivolumab-induced ILD.

###### 

Summary of Reported Patients with Anti-PD-1 Antibody-induced ILD Including the Present Case.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference      Age/sex   Cancer type    Agent    Pattern of ILD   Method of diagnosis   BALF findings   Treatment for ILD   Outcome                                       
  -------------- --------- -------------- -------- ---------------- --------------------- --------------- ------------------- --------- ------ ------ --------------------- ----------
  \(7\)          70/M      Melanoma       Nivo     ARDS             Clinical              ND              ND                  ND        ND     ND     IV steroids, IV IFX   Improved

  \(7\)          38/F      Melanoma       Nivo     ARDS             Clinical              ND              ND                  ND        ND     ND     IV steroids, IV IFX   Dead

  \(7\)          58/M      Melanoma       Nivo     NSIP             Clinical              ND              ND                  ND        ND     ND     Oral steroids         Improved

  \(8\)          70/F      Melanoma       Nivo     OP               Biopsy                7.7             38.5                43.5      13.0   0      Oral steroids         Improved

  \(9\)          70/F      Melanoma       Nivo     OP               Biopsy                2.76            58.9                37.3      2.3    1.5    IV steroids           Improved

  \(10\)         35/F      Melanoma       Nivo     DAD              Autopsy               ND              ND                  ND        ND     ND     Not described         Dead

  \(11\)         73/F      Melanoma       Nivo     DAD              Clinical              3.1             77.7                8.7       14.3   ND     mPSL pulse, IVCY      Improved

  \(12\)         64/F      Melanoma       Pembro   OP               Clinical              ND              60.7                28.7      ND     ND     IV steroids           Improved

  \(13\)         70/M      Sarcomatoid\   Nivo     OP               Clinical              11.7            65.0                32.5      2.0    0.5    Oral steroids         Improved
                           carcinoma\                                                                                                                                       
                           of the lung                                                                                                                                      

  Present case   68/M      Melanoma       Nivo     AFOP             Biopsy                6.0             5.7                 53.6      30.1   10.6   mPSL pulse            Improved
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ILD: interstitial lung disease, PD-1: programmed death-1, BALF: bronchoalveolar lavage fluid, AM: alveolar macrophages, Lym: lymphocytes, Neu: neutrophiles, Eos: eosinophiles, ND: not described, Nivo: nivolumab, Pembro: pembrolizumab, ARDS: acute respiratory distress syndrome, NSIP: nonspecific interstitial pneumonia, OP: organizing pneumonia, DAD: diffuse alveolar damage, AFOP: acute fibrinous and organizing pneumonia, IV: intravenous, IFX: infliximab, mPSL: methylprednisolone, IVCY: intravenous cyclophosphamide pulse

In 9 patients with nivolumab- or pembrolizumab-induced ILD, regardless of the pathological diagnosis, the outcome of ILD was also reported, and only 2 patients with autopsy confirmed diffuse alveolar damage (DAD) and clinically diagnosed acute respiratory distress syndrome (ARDS), respectively, died from ILD. ILD improved in 7 other patients, including 2 patients with pathologically proven organizing pneumonia. The present patient with AFOP also showed a significant improvement in his symptoms and also in the image findings after undergoing treatment with corticosteroids. Although the precise mechanisms underlying immune checkpoint inhibitor-associated pneumonitis have not yet been elucidated, a previous study reported that the infiltration and activation of T lymphocytes were commonly observed in normal tissues in patients with anti-PD-1 antibody-associated adverse events ([@B14]). Therefore, the activation of T lymphocytes may also play a role in developing pneumonitis, and this is concordant to the present patient where lymphocytosis was observed in the BALF.

The present patient also seems to be important in light of the pathogenesis of the rare disease of AFOP. The fact that this disease was evoked as an adverse event of an immune-check point inhibitor, and that marked lymphocytosis and neutrophilia in situ were confirmed by BAL, may suggest an immunological roles in the development of AFOP. Neutrophilia in BALF has also been reportedly observed in AFOP of idiopathic ([@B15]-[@B17]), drug-induced ([@B18]), lung transplantation-induced ([@B19]), and hematopoietic stem cell transplantation-induced ([@B20]).

In conclusion, the present report provides important evidence that nivolumab-induced ILD contains AFOP. The findings presented therein may provide some valuable insight into the pathogenesis of AFOP. Further elucidating nivolumab-induced ILD is therefore warranted.
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